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1. Introduction 
Epidemiological studies have shown a direct correlation between total serum cholesterol 
level and the risk of coronary disease. The significance of lowering serum total cholesterol 
(TC) and low density lipoprotein (LDL-C) and increasing high density level cholesterol 
(HDL-C) has been shown in various kinds of these studies on stroke; even on ones 
concerning cardiovascular events. The relative cardiovascular risk reduction by lowering the 
LDL-C ranges around 20-30%. The cardiac benefit of controlling serum lipid levels is specific 
among patients with evidence of chronic heart disease. Among the population without 
previous coronary disease, the primary preventive effect is less clear.  
In acute stroke, the behavior of lipids changes from day to day and even up to weeks. The 
exact behavior of lipids is not ultimately that clear and even though this issue is very old, 
the studies about it are very sparse and not up-to-date.  On the other hand, it is known that 
the specific biological effect of lowering lipids in cardiovascular and cerebrovascular 
conditions by using HMG-CoA reductase inhibitors (statins) causes a modulatory influence 
on the myocardial, vasculoprotective and neuroprotective areas of the brain. Some of the 
beneficial effects of the statins may be secondary to the “class effect” or due to the 
individual characteristics of each drug. An example of this is seen, when under the use of 
statins, there is a 1.8% reduction of body weight with a 5-7% reduction in serum LDL-C. The   
coronary beneficial preventive effect was shown with pravastatin in the West Scotland 
Coronary Prevention Study (WSCPS), with lovastatin in the Air Force coronary 
Atherosclerosis Prevention Study (AFCAPS), with atorvastatin in the Anglo-Scandinavian 
Cardiac Outcomes Study Trial (ASCOT-LLA) and with rosuvastatin in the Jupiter Study. All 
aspects of statin treatment during the acute stroke phases have not yet been clarified and 
what is known will be discussed in this chapter.   
2. Lipids during acute stroke 
2.1 Serum lipid levels during acute stroke 
Since the end of the 60’s, various articles have been published concerning the lipid level of 
stroke patients. Most studies of the studies analyzed the levels for weeks or months after 
stroke. However, none of these studies examined the lipid profile during the stroke event. In 
1987, Mendez et al. [1987] studied 22 consecutive patients in three different time points, 
within 24 hours of stroke and 7 days and 3 months later. The mean level of total cholesterol 
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(225 ± 15 mg/dl) decreased to a lower level (189 ± 19 mg/dl) after 7 days and increased 
again to a higher level (247 mg/dl) after 3 months (significance of p<0.05). In transient 
ischemic attack patients (TIA), the profile was similar, but did not reach the level on 
admission at 3 months. The levels of total cholesterol were especially high among younger 
patients significantly. The profile of very low density lipoproteins (VLDL) was a similar one 
(16 ± 6 mg/dl, 13 ± 4 mg/dl, 16.5 ± 5, respectively to the time points). There was a 
correlation between serum levels, group of age and severity of strokes with the triglycerides 
(186 ± 45 mg/dl, 173 ± 36 mg/dl, 209 ± 43mg/dl., respectively), and on the low density 
lipoprotein  (LDL) (186 ± 17 mg/dl, 149 ± 0.5 mg/dl, 202 ±19mg/dl., respectively). High 
density lipoprotein (HDL) showed a reciprocal profile (23 ± 3.0 mg/dl, 27 ± 4.5 mg/dl, 29 ± 
4.0 mg/dl., respectively). The levels were higher in aged patients and in TIA ones. The 
differences in most of the tests had not reached statistical significance. 
Woo et al. [1990] analyzed data of 171 patients during acute ischemic stroke (48 hours and 3 
months later). They found a high level of total cholesterol in the early stage of acute stroke 
(221 ± 46 mg/dl vs 205 ± 50 mg/dl, p<0.0001) and of LDL-C (147 ± 43 mg/dl vs 135 ± 46 
mg/dl, p=0.05). Triglycerides were lower on admission and non significant (133 ± 1.0 mg/dl 
vs 151 ± 89 mg/dl, p<0.0001).No changes were found in HDL and VLDL. There was a 
significant correlation toward better outcome in the higher level of total cholesterol, 
triglycerides, VLDL and HDL and reciprocal concerning HDL. The levels were lower in 
lacunar infarction patients. A significant finding was shown in lacunar infarction and was 
only higher in total cholesterol and LDL-C during the first 48 hours. 
In 1996 Aull et al. [1996] examined the data of 37 patients with TIAs or minor strokes, 
during the first 24-48 hours and compared the data to the results of other patients after 49-
168 hours. In spite of the severe limitations of the design of the study, they found a higher 
level of total cholesterol in the 24-48 hour group (231.7 ± 42.8 mg/dl vs 192.2 ± 36.0 mg/dl, 
p<0.05). There was no difference concerning the triglyceride and HDL-C levels.  
A study which analyzed the post ischemic stroke cholesterol and LDL-C levels in various 
time points – on admission; day 2 and 3; week 1, 2 3 and 4; although in only 19 patients, was 
published by Kargman et al. [1998] based on the data from the Northern Manhattan study 
(NOMIS). They found a similar profile for cholesterol and LDL-C. The highest level was on 
admission, decreased to a lower level on the second day, reaching the lowest level after 1 
week, and a recurrent increase on the 4th week, without reaching the original level on 
admission (cholesterol - 295 ± 57.6 mg/dl, 214 ± 53.2 mg/dl, 215 ± 58.2 mg/dl, 208 ±  
43.5 mg/dl, 213 ± 45.3 mg/dl, 213 ± 45.3 mg/dl, 218 ± 47.9 mg/dl and 216 ± 55.8 mg/dl; 
LDL - 154 ± 56.0 mg/dl, 137 ± 52.1 mg/dl, 133 ± 49.4 mg/dl, 124 ± 39.2 mg/dl, 131 ±  
36.6 mg/dl, 133 ± 43.3 mg/dl, 130 ± 45.6 mg/dl). The profile of triglycerides showed the 
lowest level on admission (181 ± 94.7 mg/dl) and a maximal level after the first week  
(250 ± 151.6 mg/dl). HDL-C did not show any dynamic values.  
2.2 Level of lipids during acute stroke as a prognostic marker for outcome and death 
Some studies analyzed the level of lipids during the acute state of stroke as a prognostic 
marker for the later outcome. 
2.2.1 Total cholesterol  
Vauthey et al. [2000] analyzed the data base of 3,273 consecutive patients with first ever 
stroke. They found a high mortality rate (p=0.002) and a poorer one month outcome 
(p<0.01) in correlation with low levels of total cholesterol. The association between low 
serum level of total cholesterol and worse outcome as well as with mortality rate was 
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described also by Dyker et al. in 977 patients [1997] and by Olsen et al. [2007] when 
measuring the total cholesterol in 513 patients within 24 hour time window. The 
neurological score used for evaluation was the Scandinavian Stroke Score (SSS). Li et al. 
[2008] in a prospective observational study of 649 patients, including all types of stroke and 
intracerebral hemorrhage patients also found a high level of correlation of p<0.005 between 
low levels of total cholesterol and better 90 day outcome, using the Scandinavian Stroke 
Score (SSS). The correlation between high level of serum total cholesterol and better 
outcome was confirmed during follow-up post stroke. Simundic et al. [2008] demonstrated 
these findings also in their acute stroke study which included 70 patients. Pan et al. [2008] 
examined the functional Barthel Index Scale in 109 patients in different stages of outcome at 
2 weeks and 1, 2, 4 and 6 month and confirmed this observation in each of the examination 
points. E. Cuadrado-Godia  et al. [2009] found this association in both sexes, but also more 
prominently among the male. In their study, which included 591 patients, a neurological 
score (NIH Stroke Scale), as well as a handicap score (Modified Rankin Scale – mRS) were 
used. A sex dependency was found not only in the higher levels, but also in the lipid level as 
outcome prognostic markers. The level of total cholesterol was higher among females (187.7 
± 45.0 mg/dl vs 176.7 ± 43.8 mg/dl, p=0.005). The association between high level of total 
cholesterol and better outcome was highly significant among males and not among females 
(p=0.0014). This study included naïve and non naïve statin users, as well as patients under 
tPA administration. The overall lipid level was relatively low (6% total cholesterol and >250 
mg/dl). Contrary to these results, von Budingen et al. [2008] in Switzerland analyzed 
prospectively collected data of 899 patients. Each of them neurologically scored using the 
NIHSS scale. The authors compared the scores on admission and day 90 and found no 
correlation between neurological recovery and cholesterol level.   
2.2.2 High density lipoprotein (HDL) level   
The HDL levels during acute stroke were analyzed as part of the lipid examination in Li et 
al. [2008] in 649 patients and a high correlation (p<0.001) was found between low HDL and 
severity of stroke after 90 days. Sacco et al. [2001] in a population based incident case 
controlled study, which included 539 patients with first ever ischemic stroke, evaluated a 
protective effect of high HDL-C (> 35mg/dl). The association between HDL-C level and 
better outcome more was significant in the serum level group of 35-39 mg/dl and as most 
effective in the patient group having HDL-C > 50 mg/dl. The study was designed for the 
elderly population (>75 years) of all ethnic groups. The previously mentioned study of 
Cuadrado-Godia et al. [2009] found the same tendency of higher HDL among females (52.9 
± 15.1 mg/dl vs 45.1 ± 13.4 mg/dl) and an isolated effect toward better outcome in 
association with higher HDL levels only among males (p<0.001). There was the same 
tendency in the total cholesterol/HDL ratio showing higher a ratio among males  (3.7 ± 1.2 
mg/dl vs 4.11 ± 1.4 mg/dl, p=0.002). A sex dependency was shown also by Russman et al. 
[2009].  A higher level among females (42.5 mg/dl vs 34.2 mg/dl, p=0.05) was 
demonstrated, as well as being less prone to stroke and having a better outcome (mRS 
p=0.059). It was assumed as the increase of HDL-C among females was dependent on the 
higher endogenous estrogen regulation APO AI [Hamalainen et al., 1986; Longcope et al., 
1990].       
2.2.3 Triglycerides (TG)   
The association between the level of TG and outcome is more controversial. Whereas, most 
studies showed a correlation between high level and better outcome and recovery [Li et al., 
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2008], other studies had not found a correlation or a tendency, and their results not reaching 
statistical significance [Simundic et al., 2008]. 
In summation, all studies confirmed the finding of direct, independent correlation between 
higher total cholesterol level, during acute stroke, and HDL-C and better outcome and 
recovery. This tendency was shown especially among the elderly population in different 
races and ethnicities. Some studies, in which the results were not absolutely clear, showed 
that a high triglycerol level has a tendency toward better outcome. A higher level was 
expected among females, and among males, the elevation of lipids in serum, and especially 
in total cholesterol and HDL, are of more importance as better outcome markers. 
2.3 Lipid profile and outcome after thrombolysis  in acute stroke 
Intravenous administration of tissue plasminogen activator (tPA) is an improved tool for 
better outcome in a large group of acute ischemic stroke. The main severe complication of 
tPA is secondary bleeding after the administration of the drug. The association of lipid and 
tPA was examined in severe strokes and revealed controversial data. In a retrospective 
study, which included tPA treated patients, intraarterial thrombolysis on mechanical 
embolectomy found an association between secondary hemorrhagic transformation and 
LDL cholesterol level. Bang et al. [2007] examined 104 patients checking parameters for tPA 
outcome in intravenously treated patients. They found that low LDL (odds ratio (OR) 0.968 
per 1 mg/dl) increases independently upon static treatment has a high risk for hemorrhagic 
transformation. Uyttenboogaart et al. [2008] one year later found controversial findings. 
They found no association between LDL, HDL and total cholesterol levels and usage of 
statins as predictive factors for secondary bleeding. On the other hand, they demonstrated a 
significant independent correlation between high levels of triglycerides and the risk of 
secondary bleeding, but not with unfavorable outcome in a three month analysis (p=0.53). 
Among 252 patients, they found that the mean triglyceride levels were significantly higher 
among secondary bleeding patients (2.5 mmol/L vs 1.8 mmol/L, p=0.02) and reaches 
statistical significance, p=0.01, as an independent associated factor. The difference in HDL 
level (1.0 mmol/L vs 1.2 mmol/L, p=0.03) did not reach statistical independent significance. 
Ribo et al. [2004] investigated low Lp(a), as an isolated marker for hemorrhagic 
transformation in tPA treatment, but found no association.  
2.4 Lipid and hemorrhagic transformation during acute ischemic stroke 
Most studies showed an association between low level of cholesterol and triglycerides and 
intracerebral bleeding. This assumption is controversial. Kim et al. [2009] analyzed 377 
patients of different types of stroke to investigate the association between serum lipids and 
hemorrhagic transformation. Lipid profile was evaluated on admission (< 24 hours) and 
MRI done within 1 week after stroke. They found a difference between large artery 
artheromathosis and cardioembolic origin. In large atheromatotic patients, a low level of 
LDLC was significantly independently correlated with bleeding (OR 0.46/1mmol/L 
increase, p=0.004); in the lowest quartile (≤ 25 percentile) and the OR was 0.21 (p=0.001). The 
low level of cholesterol (lower quartile OR 0.63 for 1 mmol/L increase, p=0.02) was possibly 
associated with transformation into bleeding. No association at all was found in the 
cardioembolic group.  The association between low total cholesterol and LDL-C is not yet 
established. Endothelial damage, blood extravasation around microvessels and the direct 
effect on blood brain barrier were discussed. A correlation between lipids and bleeding was 
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shown by Ramirez-Moreno, who analyzed the data of 88 intracerebral patients. There was 
no correlation between low LDL-C level and death [Ramirez-Moreno et al., 2009]. 
2.5 Conclusion 
The consensus is that total cholesterol in the LDL form decreases during acute stroke. As for 
VLDL and HDL, the acceptable consensus is that the serum level of lipids is irrelevant for 
estimation of the basic outcome of the individual, up to at least 7 days from the event. To 
estimate the real lipid level, it is best to wait for 30 days. It is also accepted that lower level 
of total cholesterol and LDL are predictor factors for a worse outcome, especially in larger 
cortical infarction strokes. However, the studies concerning this consensus are considered 
poor and include only a limited number of patients. This consensual date is also responsible 
for the examination of serum lipids only after a month in most of the acute stroke status 
studies. The very large data base of the various placebo groups of the disease of the diverse 
acute stroke studies, including ones on neuroprotection studies and a thrombolytic trial are 
not involved with lipid profile at the acute and hyperacute phases. It is also assumed that 
studying the subgroups of patients involving race, ethnicity, disease coexistence, various 
medication usage and various origins of the stroke were also neglected. A better clarification 
of such subgroups may be of importance for understanding the pathogenesis and clinical 
and therapeutic aspects in the proper care of stroke victims. 
2.6 Lipoprotein and APO Lipoprotein (APO Lp) in acute stroke   
Lipoprotein (a) was first described by Berg et al. in 1963. It was defined as a genetic 
variance of β lipoprotein and was inherited in an autosomal dominant form. The Lp(a) is a 
LDL-like molecule, consisting of Apo(a) which is linked by a disulphide bridge to 
apolipoprotein B100. Lp(a) is evaluatory being specific to humans and primates. The 
sequencing of Lp(a) at the protein and DNA levels has a high degree of similarity to 
plasminogen, leading to cross reactivity between both. A lower degree of similarity can be 
found with other “kringel” loop proteins, such as prothrombin, factor XII, and 
macrophage stimulating factor. The similarity is responsible for the endothelial cell 
fibrinolysis and the indication of procoagulant state.  
The Apo(a) gene is highly polymorphic and more than 35 different sized alleles (ranging 
from 187-648 kDa) have been identified. The size of polymorphismus of Apo (a) is mostly 
dependent upon the genetically determined number of kringel IX type 2 repeats.  
A few small studies have analyzed the quantitative profiles of Lp, APO Lp (a), and APO 
Lp(b) alongside the time axis after acute stroke. In the early 90s, Woo et al. [1990] discussed 
this topic. He examined APO Lp A1 and APO B levels in 171 patients during the first 48 
hours and 3 months later. During the acute phase, the APO Lp A1 level was higher overall in 
all stroke subjects, as well as in cortical ischemic stroke and intracerebral bleeding, but not in 
lacunar stroke. The increase was in the range of 8-10%, but did not reach statistical 
significance (122.0 ± 30.9 vs 117.4 ± 26.4 mg/dl; 121.2 ± 31.8 vs 115.6 ± 26.4 mg/dl; 127.5 ± 
34.7 vs 117.2 ± 29.8 mg/dl; and 119.1 ± 26.8 vs 119.1 ± 23.8 mg/dl; respectively). 
The level of APO B showed a similar tendency; however, the increase of APO B level 
reached statistical significance among the cortical subgroup (p<0.008) (95.6 ± 27.9 vs 87.1 ± 
23.4 mg/dl; 98.0 ± 26.5 vs 89.5 ± 27.4 mg/dl; 90.5 ± 25.3 vs 83.9 ± 22.2 mg/dl; and 98.7 ± 32.9 
vs 86.9 ± 32.9 mg/dl; respectively). The Lp(a) showed reciprocal behavior. There was a 
decrease of Lp (a) during the acute phase (among 10-15%), significantly in cortical stroke, 
but not in intracerebral bleeding. The level of Lp(a) after three months of stroke was 
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significantly high in cortical infarct also in other studies [Yingdong & Xiuling, 1999]. These 
studies were contradictory with another study which involved 127 patients, having not 
found any difference between the acute stage level and recovery stage [Misirli, 2002]. 
The NMSS (North Manhattan Stroke Study) at the end of the 90s, Lp (a), APO AI and APO B 
were examined during the acute state of 24 hours and in the follow-up stages at 2 and 3 days 
and weeks 2, 3 and 4. Nineteen subjects fulfilled all the criteria, mean age was 65.0 ± 12 years 
and all types of ischemic infarcts were included. The Lp (a) concentration was elevated (52.0 
± 28.6 mg/dl) on admission (<24 hours) and remained (>30 mg/dl) in 15 patients after 1 
month. The Lp(a) level began to decrease (46.0 ± 25.8 ) on day 3 and remained constant up to 
the 4th week (43.0 ± 29.7 mg/dl). The data did not reach statistical significance.   
The APO AI level did not show any significant changes (day 1 130.0 ± 26.4 mg/dl; day 3 
128.0 ± 27.1 mg/dl; 4th week128.0 ± 28.3 mg/dl). The APO B showed an increased level at 
the acute stage (141.0 ± 46.1 mg/dl), decreased at day 3 (131.0 ± 41.5 mg/dl) and remained 
stable up to the 4th week (132.0 ± 37.2 mg/dl). Another study, which analyzed the data of 31 
cerebral hemorrhage patients and 10 ischemic strokes, found a decrease of APO A in the 
intracerebral patient group up to the 14th day. Lp(a) levels increased simultaneously up to 
the 7th day. In the ischemic group, APO A decreased, whereas no change was observed in 
the APO B and Lp(a) levels.   
At the end of the 90’s, Seki et al. [1997] analyzed the level of Lp(a) in association with 
thrombomodulin and total cholesterol levels in 28 cerebral thrombus patients during the 
acute phase of cerebral thromboses.  The examination took place up to three days after the 
event. The event included large vessel thrombosis in lacunar infarction. The data was 
compared with 36 patients who had chronic phase cerebral thrombosis (> 1 month post 
event), 6 patients with chronic post intracerebral hemorrhage (> 3 months post event) and a 
control group of 37 volunteers. The plasma level of Lp(a) was significantly higher in the 
acute stage of cortical strokes (24.2 ± 20.9 mg/dl in cortical strokes; 13.4 ± 8.6 mg/dl in 
lacunar strokes; 24.2 ± 20.9 mg/dl in cortical strokes; and 11.6 ± 8.0 in controls; p<0.0001. 
significant higher level was found also in recurrent strokes (19.8 ± 17.6 mg/dl, p<0.05). 
Higher levels were demonstrated also in chronic post stroke phases (16.9 ± 14.7 mg/dl after 
1 months), but not in bleeding ones after 3 months. The total cholesterol levels were low as 
expected.  Van Kooten et al. [1996] in a cross sectional study which included 151 consecutive 
patients found a higher level of Lp(a) in 355 of stroke patients. The media values were 191 
(12-1539) mg/dl in stroke and 197 (10-1255) mg/dl among transient ischemic stroke 
patients. In intracerebral hemorrhage, an elevation of  Lp(a) to 153 (11-920) mg/dl was also 
found. Although the level of Lp(a) was increased in about one third of acute stroke patients, 
it was not characteristic of a stroke profile or outcome progress. These are contradictory to 
other studies having found only independent correlation between Lp (a) level and acute 
stroke [Misirli et al., 2007].  
2.6.1 Summary 
The data is inconclusive and is based on small group studies. Most of the studies indicate 
mild increase of APO AI and APO B in the acute stage after infarction lasting up to three 
days and returning to normal values after weeks or months. The data regarding Lp(a) is 
controversial. It seems that in cortical infarction the changes are more predominant, but in 
cerebral bleeding, only some of the changes may be present. The difference in results can be 
explained by the use of a very small patient sample, differences in laboratory techniques and 
homogeneity in patient populations.  
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2.7 Oxidized Low Density Lipoprotein (oxLDL) 
LDL particles can be modified into a form defined as oxidized LDL (oxLDL). It is a 
proatherogenic and proinflammatory mediator induced by the inflammatory stimuli and 
the presence of oxygen enzymes (ROS), especially myeloperoxidase and nitric oxide 
synthase (NOS). oxLDL looses the affinity to bind to LDL receptors and gains an affinity to 
bind to the protein receptor family called scavenger receptors. Their subfamily A is present 
on macrophages, platelets and other cells and has the affinity to bind and internalize the 
oxLDL particles and other cells; plus, to gather up the cholesterol in the cells and create foam 
cells.  This multi-functional membrane receptor shares also an effect on apoptotic cells and 
microbial agents. 
An important scavenger type is CD 36, which has a concrete affect on  oxLDL. The signaling 
pathways include activation of SCR family kinase, MAP kinase, and the Vav family of 
quinine nucleotide exchange factors. The CD 36 deficient animal models show inhibition of 
thrombus formation, reduction of accumulation of microparticles and inhibition of foam cell 
creation. The scavenger receptor B type I (SR-R1) plays a main role in mediating cholesterol 
exchange between cells and diverse lipoproteins.  HDL-SR-R1 is atheroprotective, 
cardioprotective and vascular protective by a direct endothelial affect on the kinase 
pathways. This includes plasma membrane cholesterol flux, requiring the C termination of 
the PDZ domain on the receptor and mediation of the membrane cholesterol binding; it 
includes also the upregularion of nitric oxide production. 
In astrocytes surrounding the tissue of infarcts, an activity of oxLDL was shown stimulating 
interleukin 6 secretion, active initiation of immunity and tissue survival [Shie et al., 2004].  The 
behavior of oxLDL during acute stroke is characterized by a significant increase of its level 
immediately after onset of infarction, lasting up to three to seven days. Uno et al. [2003] 
compared the plasma level of  oxLDL in 45 patients after acute ischemic stroke and in 11 patients 
with intracerebral bleeding and compared it to a control group. They found a highly significant 
correlation (p<0.0001) between high level of oxLDL and only cortical ischemic stroke. The mean 
values in the three groups (ischemic stroke, hemorrhagic stroke and controls) resulted in the 
following outcomes: 0.245 ± 0.22 vs 0.13 ± 0.007 and  0.179 ± 0.0232 ng/microg oxLDL. 
A second study of the same group [Uno et al., 2005] compared the oxLDL of 44 patients with 
the imaging data DWI-PWI (diffusion perfusion weighted index) mismatched. The results 
showed a statistical correlation between enlargement of the ischemic phase and the serum 
elevation of oxLDL. The correlation was specific for cortical infarcts and not for subcortical 
strokes or for huge hemispheric infarctions. The first blood sample was examined during the 
first 24 hours after infarction. The elevation profile showed a high level up to seven days 
and normalization of serum level up to 14-30 days post stroke. 
Another study compared oxLDL in 28 patients after acute atherothrombotic and lacunar 
infarction. There were significant (p<0.001) higher serum oxLDL level in  atherothrombotic 
strokes compared with the small vessel disease and control groups. The values were as 
follows: 106.85 ± 11.6 U/L; 81.0 ± 28.2 U/L; and 79.1 ± 20.4  U/L; respectively. The rationale 
for the elevation of the oxLDL during acute stroke was due to the acute increase of oxidative 
stress and induction of the adhesion molecules. 
3. Statins during acute stroke  
3.1 Statins 
Statins are competitive inhibitors of the enzyme HMG (3-hydroxy 2 – methylglutaryl) COA 
reductase. This enzyme is considered to have the most important role for limiting 
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cholesterol biosynthesis. The statin effect is based on the capacity of its binding to the active 
site of the HMG CoA reductase. Statins reduce the intrahepatic cholestasis amount, increase 
the LDL receptor turnover and reduces the VDLD production by acting on the hepatic APO 
B secretion and reduction of the plasma triglycerides level. It also acts on the clearance of 
VLDL.  
Six main statins are now on the market – lovastatin, pravastatin, simvastatin, fluvastatin, 
atorvastatin and rosuvastatine. Although all statins share the same “class effect”, there are 
predominant differences among the various types of statin drugs. The non selective 
reduction of the LDL substances, especially the small, dense LDL particles, is more specific 
for atorvastatin and rosuvastatin. The effect of increasing HDL-C in serum and the apo 
lipoprotein AI is typical for simvastatin and rosuvastatin. Rosuvastatin and atorvastatin are 
also very effective in the dynamic changes of serum triglycerides, although the individual 
effect of these diverse statins and the drug’s is very different from person to person, often 
dependent upon race and genetic ethic differences [Mangravite et al., 2008; Mangravite &  
Krauss; Puccetti et al., 2007]. 
The benefit of statins in primary and secondary prevention of coronary heart disease and 
the formation of atherosclerotic plaques is well established [Sandowitz et al., 2010a, 2010b]. 
The effect of statins on the cerebrovascular system and the brain tissue is based on their 
pleiotrophic effect beyond the direct lipid effect. The vasoeffective action is based on a direct 
upregulation of the endothelial nitric oxide synthase (eNOS), increase of the bioavialability 
of NO 20-22 [Ito et al., 2010; Laufs et al., 2000; Nakata et al., 2007; Yagi et al., 2010; Ye et al., 
2008;] and inhibition of NADPH oxidase [Antoniades et al., 2010; Rueckschloss et al., 2001]. 
This vascular effect precedes the lipid one. The decrease of the asymmetric dimethylarginine 
(ADMA) [Nishiyama et al., 2011] stabilizes the blood barrier integrity [Sierra et al., 2011], 
acts on the apoptotic pathway [Carloni et al., 2006] and stimulates excitatory  
Neurotransmitters are other targets of the statin effects concerning its action on the vascular 
system and cerebrovascular event.  
3.2 Statins in stroke 
Statins have multiple targets of action in stroke. The main confirmed activity is in the 
vasculature reactivity action on the eNOS and NO and by action on the inflammatory 
pathways. The effect was shown in animal model studies. In human ones, it was shown that 
statin pretreatment has a favorable effect on outcome. The issue of initiation of statin 
treatment during acute stroke is not yet resolved. There are indications that the efficacy may 
be dependent upon type of statins and that this effect is an individual and not a “class 
effect”. The multiple mechanisms of statins on ischemic brains are based on the different 
targets of action. Statins increase eNOS [Ito et al., 2010; Ye et al., 2008] and reduce activity of 
nicotinamide adenine dinucleotide phosphate oxidase and decrease endothelin 1 and 2 and 
the expression of AT1 receptor [Yagi et al., 2010]. It also acts on the inflammatory system by 
decreasing the nkFB [Nakata et al., 2007; Ye et al., 2008] and the expression of interleukin 
(IL) 1p, IL6 and MCP. It also has an increasing effect on expression of tPA and a decreasing 
effect on plasminogen activator inhibitor 1.  Additional targets of action are on the reactive 
oxygen species, the metalloproteinase 9 and blood brain barrier and on platelet activity 
[Sierra et al., 2011]. Also, various animal model studies demonstrated improvement in 
outcome by induced stroke on different types of models and administration of statins 
(mostly simvastatin or atorvastatin). 
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3.3 Acute stroke in patients under statin treatment 
The issue of mortality and functional outcome after ischemic stroke in patients under statin 
treatment was analyzed in different prospective and retrospective studies. As inclusion 
criteria for all the studies, statins were defined as such without characterization of the type 
of statins. The results of those studies was based on the assumption of a statin “class effect” 
for neuroprotection and as a lipid lowering agents. The data of preclinical animal model 
studies [Berger et al., 2008; Bosel et al., 2005; Carloni et al., 2006; Domoki et al., 2010; Franke 
et al., 2007; Lee et al., 2008; Moonis et al., 2005; Sironi et al., 2003; Yrjanheikki et al., 2005] 
have indicated a different neuroprotective effect of the various types of statins and raises the 
fact that all these results must be taken into consideration.  
Marti-Fabregas et al. [2004] in a prospective study, which included 167 patients, found a 
favorable outcome after three months post stroke and on statin pretreated patients 
compared with the untreated group (80% vs 51.8%, p=0.059) using handicapped mRS 
scores. Using functional disability Barthel Index (BI) scoring, similar results were found. 
Yoon et al. [2004] examined 436 patients with ischemic stroke. He found a good outcome 
(defined as mRS score >2) in 52% in the statin protected group, compared with 38% among 
controls (p=0.02).  At the same time, Greisenegger et al. [2004] confirmed the findings with a 
cross-sectional study of 1,691 patients. They found also, that among the diabetes mellitus 
patients, the percentage of bad outcome (defined as mRS score of 5-6) was 16% of the 
untreated patient group, whereas no bad outcome was found among the statin treated 
group.  
One year later, Moonis et al. [2005] compared 129 patients under previous statin treatment 
with a group of 600 untreated patients. The pretreated patient group had a significant better 
outcome at 12 weeks, using NIHSS (p=0.002) and mRS scoring (p=0.033). 
In January 2008, Reeves et al. in Michigan analyzed the data of the Paul Coverdell National 
Acute Stroke Registry. They data included 1,360 ischemic stroke patients in 15 hospitals. 
They also confirmed the previous studies. In this study, the patients under statins were 
associated with lower odds of poor outcome. There was also a significant difference among 
race. Whereas, the odds ratio among Caucasian Americans was significantly toward better 
outcome from the statin treated group (OR=0.61), the odds ratio among Afro Americans was 
non significant (OR=1.82). 
The north Dublin Population Stroke Study [Ni et al., 2011] was a population based 
prospective cohort one and included 448 ischemic stroke patients with 305 (134 patients) 
being pretreated with statins. The most common prescribed statins were atorvastatin 
(70.2%) and pravastatin (24.6%). NIHSS and the mRS scores were compared with 112 
patients of the untreated group and 189 newly post stroke statin treated group. The odds 
ratio of the pretreated group in comparison to the untreated group was 0.04 (CI 0.0-0.33, 
p=0.003) at 7 days, 0.23 (CI 0.09-058, p=0.002) at 90 days and 0.48 (CI 0.23-1.01, p=0.05) at 1 
year. The newly acute post statin group demonstrated similar results – lower OR (0.12, 
p=0.003) after 7 days, similar OR (0.16, p<0.001) after 90 days and better OR (0.26, p<0.001) 
after 1 year.  
Arboix et al. [2010] collected date on 2,082 consecutive patients with first ever ischemic 
stroke incorporated from prospective hospital based stroke registry during 19 years. They 
found a better prognosis for pretreated patients concerning death (6.0% vs 11.5%, p=0.001), 
symptom-free (22% vs 17.5%, p=0.025) and severe bad functional outcome (6.6% vs 11.5%, 
p=0.002). Imaging studies confirmed the clinical data results. Stead et al. [2009] showed also 
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that among 508 patients with ideal LDL level (≤ 100 mg/dl) the functional outcome was 
significantly better among statin users (p<0.001) [Reeves et al., 2008]. The neuroprotective 
pleiotrophic effect was assumed to be the reason for this phenomenon. Nicholas et al. [2008] 
found a smaller volume of infarcts in statin pretreated patients (p=0.01). Ford et al.[2011]  
examined the reperfusion in acute ischemic stroke using MR scan within 4.5 hours and 6 
hours. Twelve of the patients were statin pretreated and 19 were not. They found a 
significant better reperfusion among the treated group (50% vs 13%, respectively; p=0.014). 
The findings were in association with improvement of NIHSS scores after one month.  
3.3.1 Summary 
All trial data indicate a significantly better for pre users of statin in ischemic stroke. This 
finding included mortality rate, early and late handicap and functional outcomes, as well as 
Neuroimaging findings.  
3.4 Satin treatment withdrawal during acute stroke 
The assumption that sudden discontinuation of statins may have a critical effect on the body 
is based on its biological characteristics and observations within in vitro studies and in vivo 
animal models. These studies showed dramatic down regulation of eNOS expression and 
reduction of eNOS protection up to 90%. This process is dependent upon changes in Rho 
and Rac regulation and changes in activity of Rho kinase. Platelet factor 4 and 
thromboglobulin change as well. This significant involvement in the vascular endothelial 
biology may, as usual, have a rebound effect. There are studies showing almost complete 
disappearance of the statin protective effect in experimental acute stroke after 
discontinuation of the drug for two days [Chen et al., 2005; Karki et al., 2009]. Changes of 
cerebral blood flow, in the posterior circulate system, was observed as well [Berger et al., 
2008; Xu et al., 2008]. In humans during a randomized controlled study, Blanco et al. [2007] 
examined the effect of discontinuation of atorvastatin 20 mg / day in cortical stroke 
patients’ outcomes. Of 219 patients, 89 were pretreated with statins, 43 continued the study 
and 43 stopped for 3 days. The data analysis showed high percentage of bad outcome  
(mRS > 2) among discontinued patients (60% vs 39%, p=0.043); a worse early neurological 
outcome (day 4-7 using NIHSS score, p=0.002) and a significant larger volume of stroke 
(p<0.0001). In comparison of the patient group naïve to statins, the risk of worse early 
neurological outcome was 19.01 and the risk of larger infarcts was 13.51 in total. However, 
meta analysis of 18 studies, enrolling 14,303 patients after acute coronary syndrome and 
initiation of statins within 14 days following event did not find reduction of stroke, similar 
to all cause mortality and heart attacks in a period of a four month follow-up.  
3.4.1 Summary 
The preclinical experimental data raise the speculation of a serious ‘rebound’ effect by the 
discontinuance of statins towards a worse outcome. There are too few clinical studies 
confirming this hypothesis.    
3.5 Satin in tissue Plasminogen Activator (tPA) ischemic stroke patients 
The association between statin treatment and intracerebral hemorrhage, especially after 
publication of the results of the SPARCL study [Goldstein et al., 2008; Goldstein et al., 2009; 
Welch, 2009], raises the very genuine issue of the adverse event after tPA treatment.  
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3.5.1 Intravenous tPA (IVtPA)  
Uyttenboogaart et al. [2008] analyzed the data of 252 patients treated with tPA. They found 
that high level of triglycerides and low level of HDL were independent risk factors for 
bleeding (p==0.02, p=0.03, respectively). However, there was no association between statins 
and 90 day outcome. Makihara et al. [2010] analyzed the data of the Japanese SAMURAI 
rtPA Registry and confirmed the well established fact that administration of IV tPA 
increases the risk of intracerebral hemorrhage, but increases also the rate of favorable 
outcome. The usage of statins did not influence any of these findings. Miedema et al. [2010] 
published the results of a prospective observational cohort study of 476 patients treated 
with IV tPA with 20% of the patients being on statins. They did not find any favorable effect 
for 90 days in functional and neurological outcome (OR 1.1, P=0.87). This tendency was 
consistent in all five groups of stroke subtypes according to the TOAST classification. On the 
other hand, no increase of bleeding was observed as well.  
3.5.2 Intraarterial tPA  
Meier et al. [2009] in a monocenter study of 311 consecutive patients, of whom 18% were 
statin pretreated, found a higher rate of intracerebral bleeding among statin users (OR 3.1, 
P=0.004). This fact was unrelated to the 90 day functional and neurological outcome. The 
group of statin users included atorvastatin (36.4%), pravastatin (36.4%) and simvastatin 
(unknown %) users. Restrepo et al. [2009] examined the impact of statins before and after 
intraarterial fibrinolysis and percutaneous mechanical embolectomy. The study was a single 
center one in Los Angeles. Statin use was related to a better outcome with decrease of 6.5 
units in the NIHSS score after discharge (P=0.016). There was no increase in the post 
procedure bleeding. 
3.5.3 Summary  
The data of the statin effect on tPA is sparse. However, it seems that intravenous 
administration has no beneficial effect of a better outcome, but also no higher rates of 
secondary bleeding adverse events.  
3.6 Onset of satin treatment during acute stroke 
The pleiotropic neuro- and vasculoprotection effect is already described. Simvastatin, 
rosuvastatin, atorvastatin and pravastatin had been shown to have a neuroprotective effect 
in animal models. It has been shown that simvastatin reduces stroke volume in rats up to 
50% and pravastatin reduces the cerebral post stroke edema [Mariucci et al., 2011]. The 
usage of an intravenous statin in stroke is based on the intravenous formulation of the 
hydrophile types of statins – rosuvastatin and pravastatin. Rosuvastatin in intraperitoneal 
administration in rats improved clinical outcome and infarct volume [Prinz et al., 2008]. In 
humans, the studies are few. According to the latest updated cholesterol management 
guidelines, it is recommended that anticholesterol treatment be performed immediately 
after stroke. In the North Dublin Study, 134 out of 445 patients (30.1%) had begun the 
treatment during the first 72 hours after admission and 7% were treated with atorvastatin 
and 24% with pravastatin. The early and late survival and outcome were significantly better 
compared with the no treated group and equivalent to the previous statin treated group. In 
the data of the FASTER study concerning the assessment of minor stroke and transient 
ischemic attacks (TIAs) to prevent early recurrency, the group of patients under simvastatin 
within 24 hours of onset showed an increase of absolute risk of 3.3% toward bad outcome 
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[Kennedy et al., 2007]. Montaner et al. [2008] performed a simvastatin placebo controlled 
study of 60 patients having cortical stroke and receiving simvastatin 3-12 hours after onset 
of symptoms and found significant improvement after 3 days (44.4% vs 17.9%, p=0.022), but 
also a higher, non significant rate of mortality (OR 2.4 CI 1.06-5.4).  
A head-to-head study was performed by Lampl et al. [2010] and included 371 patients. The 
administration of statin was immediate comparing three elements - simvastatin and 
atorvastatin at 40mg/daily and 80 mg/daily. The statistical analysis indicated that the 
subjects receiving simvastatin had a highly significant worser outcome as noted by 
neurological (NIHSS score) and functional (mRS) measurements compared with the two 
dose atorvastatin treated patients (p<0.001). The scores of atorvastatin 80 mg were 
marginally better than those of atorvastatin 40 mg (p=0.08). 
3.6.1 Summary 
The complete picture of statins as neuroprotectors during the acute phase of stroke is not yet 
resolved. Very few studies have been performed. It is plausible to assume that the 
pleiotropic neuroprotective effect is an individual characteristic of each drug and not a part 
of a “class effect”. Many more studies and positive data are needed to confirm this 
assumption.  
3.7 Satin in acute subarachnoid hemorrhage 
The rationality of administration of statins in subarachnoid hemorrhage is based on the fact 
that statins have an effect on eNO and eNOS, as well as an anti-inflammatory mechanism. 
Therefore, it is assumed that statins may have an anti-vasospastic effect. These hypotheses 
were confirmed in animal studies using simvastatin. There have been some meta analysis 
studies which calculated the effect of statins on subarachnoid hemorrhage. Sillberg et al. 
[2008] published one meta analysis in 2008. Most of the studies used simvastatin in dosages 
of 20 mg/d and 80 mg/d  and pravastatin at 40 mg/d. Sillberg et al.’s [2008] meta analysis 
consisted of three randomized controlled trials and incorporated the studies of Lynch et al. 
[2005], Tseng et al. [2005] and Chou al. [2008]. The overall number of included patients was 
only 158. The  authors found that the incidence of vasospasm (RR 0.75 CI 0.54-0.99), delayed 
ischemic deficits (RR 0.38 CI 0.17-0.83) and mortality (RR 0.22 CI 0.06-0.82) were 
significantly reduced in the statin treated group.  
Vergouwen et al. [2009] published another metal analysis of 4 studies and included 190 
patients. Two studies were about simvastatin and one about pravastatin. No beneficial effect 
concerning transcranial Doppler vasospasm, delayed cerebral ischemia, poor outcome or 
mortality was found.   
3.7.1 Summary 
Although preclinical and various single center studies have been very promising, a positive 
conclusion about the benefit of statins in subarachnoid hemorrhage has not yet been 
finalized.  
3.8 Satin in acute intracerebral hemorrhage 
Previous studies on animals showed a significant improvement of functional outcome after 
use of simvastatin or atorvastatin, as well as reduction of hematoma volume at four weeks 
(Karki). Enhancement of neuroprotection and neuroplasticity effects in rats was assumed.  
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In humans, some studies analyzing the outcome of intracerebral hemorrhage patients under 
statin treatment. In a retrospective cohort study, Fitz-Maurice et al. [2008] compared the 
outcome of  149 patients pretreated with statins with 480 untreated patients. They found no 
difference among the groups concerning mortality, functional outcome and volume of 
hematoma. In a small group study, Tapia-Perez et al. [2009] examined 18 patients under 
ruravastatin with a control group of statin non users. The mortality rate was 5.6% among 
users and 15.8% in the control group. In Israel, two studies have been published. Eichel et al. 
[2010] found that the mortality rate among 101 statin pretreated patients was 45.5%, 
whereas the percentage among 298 non treated patients was 56.1%, p=0.04). The other 
Israeli study based on the data of the Israel Stroke Survey, compared 89 patients statin 
pretreated patients with a 312 untreated patient group. The patients under statin treatment 
had a better baseline neurological status or better outcome and a lower mortality rate  
[Leker et al., 2009]. In a prospective ascertained cohort study, Biffi et al. [2011] compared 238 
statin pretreated intracerebral hemorrhage patients with 461 non treated patients. They 
extended their own results into a meta analysis of previously published data – for a total of 
698 vs 1,823 patients. They found a favorable outcome for pretreated patients (OR 2.8 CI 
1.37-3.17) and reduced mortality (OR 0.47 CI 0.32-0.70) at 90 days. The meta analysis results 
confirmed this finding concerning better outcome (OR 1.1 CI 1.38-2.65) and mortality (OR 
0.55 CI 0.42-0.72).  
3.8.1 Summary 
Most published studies indicated a better outcome and reduced mortality among pretreated 
statin patients having intracerebral hemorrhage. Final decision on these issues must wait for 
more studies and those with a greater number of participants. No data is available 
concerning the issue of beginning statin treatment during the acute phase of intracerebral 
hemorrhage.  
 
      
 
Probable 
better 
outcome 
Possible 
better 
outcome 
Inconclusive
Probable 
worser 
outcome 
Possible 
worser 
outcome 
      
AIS under statin pretreatment +     
AIS under statin withdrawal     + 
AIS under statin and IV tpa   +   
AIS under statin and IAtpa  +    
AIS under statin as acute 
phase therapy 
 +    
SAH and statins  +    
ICH and statins  +    
Probable outcome dependent 
upon type of statin 
 +    
      
Abbreviations: AIS-acute ischemic stroke; tpa-tissue plasminogen activator; IV- intravenous;  
IA-intra-arterial; SAH-subarachnoid hemorrhage; ICH-intracerebral hemorrhage 
Table 1. Statin efficacy during acute stroke 
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4. Conclusion 
There are evidences of a favorable effect of statins in the different types of stroke. The 
efficacy was demonstrated in ischemic and hemorrhagic stroke. Most studies show a better 
recovery and decrease of mortality rate among statins pretreated patients, who did not 
discontinued the treatment.  A newly treatment with statin during the acute phase of stroke 
maybe indicated. The pleiotrophic effect of statins may play a key role in the positive effect 
of statins.  It is plausible that this effect is not a class effect of the statin group, but is an 
individual effect of each the drugs. Much larger well designed studies must be performed to 
confirm these assumptions. 
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